Impaired oxidation of debrisoquine in patients with perhexiline neuropathy.

@article{Shah1982ImpairedOO,
  title={Impaired oxidation of debrisoquine in patients with perhexiline neuropathy.},
  author={R. Shah and N. S. Oates and J. Idle and R. Smith and J. Lockhart},
  journal={British Medical Journal (Clinical research ed.)},
  year={1982},
  volume={284},
  pages={295 - 299}
}
The use of perhexiline maleate as an antianginal agent is occasionally associated with side effects, particularly neuropathy and liver damage. The reason why some individuals develop these toxic reactions is not clear, though some evidence suggests that they may result from impaired oxidative metabolism, due to genetic or hepatic factors, and consequential accumulation of the drug in toxic concentrations. Drug oxidation was measured with an oxidation phenotyping procedure in 34 patients treated… Expand
Impaired oxidation of debrisoquine in patients with perhexiline liver injury.
TLDR
A clear association exists between per hexiline liver injury and diminished drug metabolic activity, suggesting that the propensity to develop perhexiline Liver injury is, at least in part, genetically determined. Expand
Extensive oxidative metabolism of dextromethorphan in patients with almitrine neuropathy.
TLDR
This result shows that, in contrast to perhexiline neuropathy, almitrine neuropathy is not related to slow oxidation of the compound with regard to the particular P-450 iso-enzyme involved in dextromethorphan and debrisoquine metabolism. Expand
Thalidomide-induced neuropathy and genetic differences in drug metabolism
TLDR
In conclusion, changes of nerve conductivity are a frequent and unpredictable adverse effect of thalidomide (≤200 mg/day), although smoking may have a protective action against their development. Expand
Clinical implications of the competitive inhibition of the debrisoquin-metabolizing isozyme by quinidine.
TLDR
Clinicians should be alert to unusual drug reactions in patients receiving quinidine concurrently with the other medications because no test is commonly available to determine directly the debrisoquin metabolic phenotype. Expand
Polymorphic hydroxylation of perhexiline maleate in man.
TLDR
Pretreatment phenotyping using this test, followed by exclusion of poor metabolisers from perhexiline therapy, should substantially reduce the incidence of major adverse effects. Expand
Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal.
  • M. Lennard
  • Biology, Medicine
  • Pharmacology & toxicology
  • 1990
TLDR
For most sparteine/debrisoquine-related substrates there is a need for controlled prospective studies to define the consequences to the patient of impaired or enhanced drug oxidation. Expand
Perhexiline maleate treatment for severe angina pectoris--correlations with pharmacokinetics.
TLDR
It is concluded that perhexiline is useful both as a short-term adjunct to anti-anginal therapy and in the long-term management of patients unsuitable for coronary artery bypass grafting. Expand
Studies on the metabolism of perhexiline in man
TLDR
The disposition of perhexiline and its two major metabolites, M1 and M3, in healthy volunteers and in patients with biliary T-tube drains after cholecystectomy is studied, suggesting the possibility of enterohepatic recycling of these compounds. Expand
Pleiotropic mechanisms of action of perhexiline in heart failure
TLDR
The re-purposing of the anti-anginal drug perhexiline has resulted in symptomatic improvements in heart failure patients and the inhibition of carnitine palmitoyltransferase-1 (CPT-1) has been proposed as the primary mechanism underlying the therapeutic benefit of PHX. Expand
Metoprolol‐induced hepatitis: Is the rate of oxidation related to drug‐induced hepatotoxicity?
TLDR
The first case of hepatitis induced by metoprolol and the result of drug oxidation phenotyping is reported, which strongly suggests that metoprool oxidation depends at least partly on the same isozyme of cytochrome P‐450 involved in the genetic polymorphism of oxidation of debrisoquine and other drugs such as sparteine, perhexiline, and other beta‐adrenoreceptor antagonists. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 53 REFERENCES
Phenylbutazone and isoniazid metabolism in patients with liver disease in relation to previous drug therapy.
TLDR
The plasma half-life (T 1/2) of two drugs has been measured to investigate whether liver disease impairs drug metabolism in man and to assess the effect of a drug in both healthy individuals and those with liver disease. Expand
Polymorphism of carbon oxidation of drugs and clinical implications.
TLDR
The hydroxylation defect shown for debrisoquine metabolism carries over to the oxidative metabolism of phenacetin and guanoxan, and methods for evaluating the metabolism of new drugs in respect of usage and side effects need to be revised. Expand
Perhexiline maleate-induced cirrhosis.
TLDR
The cases of 2 patients who died from cirrhosis after receiving perhexiline maleate, a drug widely used in Europe for the treatment of angina pectoris, are reported, consistent with the view that prolonged administration of per hexilinemaleate may induce both histologic lesions resembling those of alcoholic liver disease and ultrastructural and histochemical lesions resemblingThose of phospholipidosis. Expand
Influence of DH/DL alleles regulating debrisoquine oxidation on phenytoin hydroxylation
TLDR
It is concluded that the metabolic oxidation of phenytoin is influenced by the same DH and DL alleles, acting at the same locus, that regulate the hydroxylation of debrisoquine and that impaired metabolism of phenYtoin may be expected to occur in about 9% of the population, being transmitted as an autosomal‐recessive trait. Expand
Hypotensive response to debrisoquine and hydroxylation phenotype.
TLDR
It is concluded that the genetic factor which controls the metabolism of debrisoquine is also largely responsible for the differences in response seen between the two debrisquine hydroxylator phenotypes. Expand
Toxicological implications of polymorphic drug metabolism.
TLDR
A new genetic polymorphism of drug metabolism has been described and it promises to provide a better understanding of inter-individual variability in the metabolic handling of, and responsiveness to, drugs and toxic substances. Expand
Liver damage associated with perhexiline maleate.
TLDR
Two patients who developed biochemical and histological evidence of hepatitis while taking the anti-anginal drug perhexiline maleate are described, including in one patient the presence of material which by light microscopy was indistinguishable from Mallory's alcoholic hyalin. Expand
POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN
TLDR
Family studies supported the view that alicyclic 4-hydroxylation of debrisoquine is controlled by a single autosomal gene and that a defect in this metabolic step is caused by a recessive allele. Expand
Hepatic Disease and Drug Pharmacokinetics
TLDR
It is not now possible to predict in an individual the influence of a specific hepatic disease on the disposition of a drug, with the exception that the oral availability of drugs with high hepatic extraction ratios is increased in patients with cirrhosis and portacaval shunting of blood. Expand
Proximal myopathy after perhexiline maleate treatment.
TLDR
It is shown that in patients with hypopituitarism both CSF and plasma p-MSH concentrations are maintained within the normal range, the CSF: plasma ratio remaining normal at about 3:1, which suggests that MSH peptides are produced by the central nervous system as well as acting on it. Expand
...
1
2
3
4
5
...